CX Institutional’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $533K | Buy |
5,897
+631
| +12% | +$52.9K | 0.02% | 463 |
|
|
2026
Q1 | $422K | Buy |
5,266
+728
| +16% | +$60K | 0.01% | 507 |
|
|
2025
Q4 | $387K | Buy |
4,538
+218
| +5% | +$17.9K | 0.01% | 497 |
|
|
2025
Q3 | $336K | Buy |
4,320
+6
| +0.1% | +$469 | 0.01% | 535 |
|
|
2025
Q2 | $337K | Buy |
4,314
+416
| +11% | +$31K | 0.01% | 470 |
|
|
2025
Q1 | $283K | Sell |
3,898
-70
| -2% | -$5.01K | 0.01% | 496 |
|
|
2024
Q4 | $294K | Buy |
+3,968
| New | +$278K | 0.01% | 450 |
|
|
2024
Q3 | – | Sell |
-3,775
| Closed | -$349K | – | 562 |
|
|
2024
Q2 | $349K | Sell |
3,775
-38
| -1% | -$3.37K | 0.02% | 425 |
|
|
2024
Q1 | $364K | Buy |
3,813
+1,240
| +48% | +$104K | 0.02% | 417 |
|
|
2023
Q4 | $196K | Sell |
2,573
-1,059
| -29% | -$73.7K | 0.01% | 492 |
|
|
2023
Q3 | $252K | Sell |
3,632
-885
| -20% | -$71.1K | 0.01% | 437 |
|
|
2023
Q2 | $426K | Buy |
4,517
+131
| +3% | +$11.4K | 0.02% | 365 |
|
|
2023
Q1 | $361K | Buy |
4,386
+434
| +11% | +$34.1K | 0.02% | 386 |
|
|
2022
Q4 | $295K | Buy |
+3,952
| New | +$305K | 0.02% | 431 |
|
|
2022
Q3 | – | Sell |
-1,212
| Closed | -$115K | – | 683 |
|
|
2022
Q2 | $115K | Buy |
+1,212
| New | +$125K | 0.01% | 532 |
|
|
2021
Q4 | – | Sell |
-1,243
| Closed | -$141K | – | 519 |
|
|
2021
Q3 | $141K | Buy |
1,243
+89
| +8% | +$10.2K | 0.01% | 396 |
|
|
2021
Q2 | $120K | Buy |
1,154
+409
| +55% | +$38.6K | 0.01% | 409 |
|
|
2021
Q1 | $62K | Sell |
745
-57
| -7% | -$4.82K | 0.01% | 451 |
|
|
2020
Q4 | $73K | Buy |
802
+269
| +50% | +$22.3K | 0.01% | 396 |
|
|
2020
Q3 | $43K | Buy |
533
+211
| +66% | +$16.5K | ﹤0.01% | 409 |
|
|
2020
Q2 | $22K | Buy |
322
+82
| +34% | +$5.83K | ﹤0.01% | 420 |
|
|
2020
Q1 | $15K | Buy |
240
+90
| +60% | +$6.49K | ﹤0.01% | 411 |
|
|
2019
Q4 | $12K | Hold |
150
| – | – | ﹤0.01% | 408 |
|
|
2019
Q3 | $11K | Buy |
150
+12
| +9% | +$843 | ﹤0.01% | 449 |
|
|
2019
Q2 | $8K | Hold |
138
| – | – | ﹤0.01% | 523 |
|
|
2019
Q1 | $9K | Buy |
138
+111
| +411% | +$6.33K | ﹤0.01% | 470 |
|
|
2018
Q4 | $1K | Buy |
+27
| New | +$1.37K | ﹤0.01% | 491 |
|
Other funds holding EW
CX Institutional's EW Position: Q2 2026 in Review
CX Institutional increased its Edwards Lifesciences (EW) stake by 12% in Q2 2026, buying an estimated $52.9K and bringing the position to 5,897 shares worth $533K. The position accounts for 0.02% of the portfolio, ranked #463.
CX Institutional first reported a position in EW in Q4 2018 and has held it in 27 quarters since. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- CX Institutional held 5,897 shares of Edwards Lifesciences worth $533K as of Q2 2026.
- CX Institutional bought 631 Edwards Lifesciences shares in Q2 2026, an estimated $52.9K.
- Edwards Lifesciences made up 0.02% of CX Institutional's portfolio in Q2 2026, its #463 holding.
- CX Institutional first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 27 quarters since.
- 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.